8-K: Enzon, Viskase Amend Merger Terms; Viskase Gains Control

Enzon Pharmaceuticals and Viskase Companies have amended their merger agreement, granting Viskase stockholders 55% ownership of the combined entity and extending the closing deadline.

Summary

• Merger Agreement and Support Agreement amended on October 24, 2025, due to "recent developments in the operations of Viskase."
• Viskase stockholders will now own 55% of the combined company, an increase from the original terms.
• Enzon's Series C Preferred Stock exchange ratio will be based on the 20-day volume weighted average price (VWAP) of Enzon Common Stock prior to October 24, 2025.
• Enzon's minimum cash requirement at closing has been reduced to $40,000,000.
• Enzon will effect a 1-for-100 reverse stock split prior to the merger.
• The merger termination date has been extended from December 31, 2025, to March 31, 2026.
• Enzon and Merger Sub waived any known inaccuracies, breaches, or non-compliance by Viskase in the original Merger Agreement occurring on or prior to October 24, 2025.
• The definition of "Viskase Material Adverse Effect" was modified to exclude effects from facts known to Enzon/Merger Sub prior to October 24, 2025.
• Icahn Enterprises Holdings L.P. (IEH) agreed to approve the merger and related corporate actions, and exchange its Series C Preferred Stock for Enzon Common Stock.
• The combined company will be named Viskase Holdings, Inc.
• Enzon believes its net operating losses and other tax benefits will be maintained for the combined company.
• Both Enzon and Viskase Special Committees, and their respective Boards, approved the amendments.

Sentiment

Score: 4

Explanation: The amendments reflect significant concessions by Enzon, including increased ownership for Viskase shareholders, a reduced cash requirement, and a waiver of known Viskase breaches. The reverse stock split and merger delay are also negative indicators. While the merger proceeds, the revised terms are less favorable for Enzon's existing shareholders.

Positives

• The merger is still proceeding, providing a path forward for Enzon as an acquisition vehicle.
• Enzon believes its net operating losses (NOLs) and other tax benefits will be maintained for the combined company, which could be valuable.
• Fairness opinions were received from financial advisors for both Enzon and Viskase special committees regarding the amended exchange ratio.

Negatives

• Viskase stockholders will own a larger share (55%) of the combined company, diluting existing Enzon shareholders' proportional ownership.
• Enzon's minimum cash requirement at closing was reduced to $40,000,000, potentially indicating less financial strength for the combined entity or Enzon's current position.
• Enzon will effect a 1-for-100 reverse stock split, often a sign of a low stock price and potential delisting risk.
• Enzon and Merger Sub waived known breaches or inaccuracies by Viskase prior to October 24, 2025, suggesting Viskase had operational or disclosure issues that Enzon is now overlooking.
• The modification of the Viskase Material Adverse Effect definition further limits Enzon's ability to terminate the agreement based on pre-amendment issues.

Risks

• Conditions to the closing of the proposed transaction may not be satisfied, including failure to obtain necessary approvals.
• Uncertainties exist regarding the timing of the consummation of the proposed transaction and the ability of Enzon and Viskase to complete it.
• Viskase may not be able to timely deliver the financial statements required by the amended Merger Agreement.
• Anticipated benefits of the proposed transaction, such as revenues, expenses, earnings, financial results, growth, expansion, and tax treatment, may not be realized.
• Potential litigation related to the proposed transaction could be instituted against Enzon, Viskase, or their respective officers or directors.
• Possible disruptions from the proposed transaction could harm Enzon's or Viskase's respective businesses.
• Viskase may face challenges in retaining, attracting, and hiring key personnel.
• Potential adverse reactions or changes to relationships with customers, employees, suppliers, or other parties may result from the announcement or completion of the proposed transaction.
• Business uncertainty, including changes to existing business relationships, during the pendency of the proposed transaction could affect Enzon's or Viskase's financial performance.
• Certain restrictions during the pendency of the proposed transaction may impact Enzon's or Viskase's ability to pursue certain business opportunities or strategic transactions.
• The exchange ratio and relative ownership levels as of the closing of the transactions contemplated by the amended Merger Agreement are subject to change.
• Estimates regarding future revenue, expenses, and capital requirements following the closing of the transactions may be inaccurate.
• Legislative, regulatory, and economic developments could adversely affect the combined company.
• Unpredictability and severity of catastrophic events, including acts of terrorism, trade wars, or outbreak of war or hostilities, could impact operations.

Future Outlook

The combined company, to be named Viskase Holdings, Inc., is expected to maintain Enzon's net operating losses and other tax benefits. The merger is now anticipated to close by March 31, 2026, following the satisfaction of various conditions, including stockholder approvals and regulatory filings.

Management Comments

• Enzon believes that the Merger as revised pursuant to the terms of the Merger Agreement Amendment will result in Enzon's net operating losses and other tax benefits to be maintained and available for use by the combined company following the Merger.

Industry Context

Enzon Pharmaceuticals, primarily an acquisition vehicle, is merging with Viskase Companies, a producer of non-edible cellulosic, fibrous, and plastic casings for processed meat products. This transaction represents a strategic shift for Enzon into the food packaging and processing industry, moving away from its pharmaceutical origins. The amendments reflect adjustments based on Viskase's recent operational performance, indicating potential challenges or changes within the food casing sector that necessitated revised merger terms.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• Potential litigation relating to the proposed transaction that could be instituted against Enzon, Viskase or their respective officers or directors.

Related Party Transactions

• Icahn Enterprises Holdings L.P. (IEH) and its affiliates are parties to the Support Agreement and its amendment, agreeing to approve the merger and exchange their Series C Preferred Stock for Enzon Common Stock. IEH is a significant shareholder.

Stakeholder Impact

• Shareholders (Enzon): Will experience dilution as Viskase stockholders gain 55% ownership. Will undergo a 1-for-100 reverse stock split. Will need to approve the amended merger and corporate changes.
• Shareholders (Viskase): Will gain a controlling 55% ownership stake in the combined company.
• Employees (Viskase): Ability to retain, attract, and hire key personnel is a risk factor mentioned.
• Customers/Suppliers: Potential adverse reactions or changes to relationships are mentioned as a risk.
• Management: New board composition for the combined company.

Next Steps

• Enzon to prepare and file a registration statement on Form S-4 with the SEC, including a consent solicitation statement.
• Seek written consent from Enzon's stockholders for the amended Merger Agreement, the transactions, and the amendment to Enzon's certificate of incorporation (name change and reverse stock split).
• Enzon to effect a 1-for-100 reverse stock split prior to the effective time of the Merger.
• Enzon's Board of Directors to permit the Section 382 Rights Agreement to expire or cause its termination prior to the Effective Time.
• IEH to deliver written consents approving the Merger and certificate of incorporation amendment.
• IEH to exchange all Series C Preferred Stock for Enzon Common Stock prior to the Merger consummation.
• The Merger is expected to occur by March 31, 2026.

Key Dates

Recommendation

The amended merger terms introduce several unfavorable elements for existing Enzon shareholders, including significant dilution (Viskase shareholders gaining 55% ownership), a reduced minimum cash requirement for Enzon, and a 1-for-100 reverse stock split which often signals underlying stock price weakness. Furthermore, Enzon waived known breaches by Viskase, suggesting potential undisclosed issues. While the merger is still on track, the concessions made by Enzon make the deal less attractive. A 'hold' recommendation is appropriate for existing shareholders to await further developments and the full S-4 filing, but new investment is not advisable given the revised terms.

Keywords

Merger Agreement Amendment, Viskase Companies, Enzon Pharmaceuticals, Reverse Stock Split, Exchange Ratio, SEC Filing, Corporate Governance, Icahn Enterprises, Preferred Stock Exchange, Material Adverse Effect, Tax Benefits, Pharmaceuticals, Food Casings